FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600586474> ?p ?o ?g. }

• W2600586474 endingPage "1984" @default.
• W2600586474 startingPage "1981" @default.
• W2600586474 abstract "We evaluated the in vitro activity of different antimicrobial combinations with and without colistin against 39 carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains (colistin + meropenem/doripenem, colistin + tigecycline, colistin + rifampicin, gentamicin + meropenem, gentamicin + tigecycline and the double-carbapenem regimen meropenem + ertapenem) using the chequerboard method. The triple combination colistin + meropenem + tigecycline was also tested. In addition, killing studies were performed for meropenem + ertapenem.Gentamicin-based combinations showed a high level of synergy. Meropenem + ertapenem was synergic in 12/39 (30.7%) of the strains, whereas based on killing studies 1 × MIC meropenem + 1 × MIC ertapenem and 2 × MIC meropenem + 1 × MIC ertapenem combinations were bactericidal and synergic at 24 h [mean area under the bactericidal curve (AUBC) 54.9 ± 26.1 and 44.2 ± 15.3 compared with 1 × MIC meropenem (134.5 ± 40.1) and 2 × MIC meropenem (126.4 ± 5.4), respectively, P < 0.0001]. When the results were stratified according to meropenem MIC, we found that the degree of synergy significantly increased for isolates with lower meropenem (and not ertapenem) MICs, up to an MIC of 128 mg/L. Among colistin-containing combinations, synergy was observed in 18/39 (46.1%), 33/34 (97%), 24/39 (61.5%) and 17/39 (43.5%) of the strains for colistin + meropenem, colistin + rifampicin, colistin + tigecycline and colistin + doripenem, respectively, including colistin-resistant strains. Colistin + meropenem + tigecycline at subinhibitory concentrations resulted in the absence of growth of 37/39 strains (94.8%).Our in vitro data suggest that colistin might be a valid therapeutic option against CR-Kp, even in the presence of colistin resistance, whereas the double-carbapenem regimen represents a viable option when colistin is not recommended, especially if the meropenem MIC is ≤ 128 mg/L. Since traditional antimicrobial susceptibility reports are not sufficiently informative for clinicians, synergy testing as well as actual meropenem MIC evaluation should always be performed in the case of CR-Kp infections." @default.
• W2600586474 created "2017-04-07" @default.
• W2600586474 creator A5008183147 @default.
• W2600586474 creator A5011249298 @default.
• W2600586474 creator A5015578772 @default.
• W2600586474 creator A5021969681 @default.
• W2600586474 creator A5030751316 @default.
• W2600586474 creator A5032150090 @default.
• W2600586474 creator A5034324107 @default.
• W2600586474 creator A5041364373 @default.
• W2600586474 creator A5051815564 @default.
• W2600586474 creator A5053977177 @default.
• W2600586474 creator A5073384798 @default.
• W2600586474 creator A5075572192 @default.
• W2600586474 date "2017-03-22" @default.
• W2600586474 modified "2023-10-14" @default.
• W2600586474 title "In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value" @default.
• W2600586474 cites W1612376079 @default.
• W2600586474 cites W1650350722 @default.
• W2600586474 cites W1978370571 @default.
• W2600586474 cites W1984558570 @default.
• W2600586474 cites W2013883719 @default.
• W2600586474 cites W2015816720 @default.
• W2600586474 cites W2018129445 @default.
• W2600586474 cites W2043639362 @default.
• W2600586474 cites W2099570276 @default.
• W2600586474 cites W2109908798 @default.
• W2600586474 cites W2110771759 @default.
• W2600586474 cites W2113219413 @default.
• W2600586474 cites W2145111808 @default.
• W2600586474 cites W2152155052 @default.
• W2600586474 cites W2162268639 @default.
• W2600586474 cites W2164697816 @default.
• W2600586474 cites W2179187685 @default.
• W2600586474 cites W2537910475 @default.
• W2600586474 doi "https://doi.org/10.1093/jac/dkx084" @default.
• W2600586474 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28369424" @default.
• W2600586474 hasPublicationYear "2017" @default.
• W2600586474 type Work @default.
• W2600586474 sameAs 2600586474 @default.
• W2600586474 citedByCount "29" @default.
• W2600586474 countsByYear W26005864742017 @default.
• W2600586474 countsByYear W26005864742018 @default.
• W2600586474 countsByYear W26005864742019 @default.
• W2600586474 countsByYear W26005864742020 @default.
• W2600586474 countsByYear W26005864742021 @default.
• W2600586474 countsByYear W26005864742022 @default.
• W2600586474 countsByYear W26005864742023 @default.
• W2600586474 crossrefType "journal-article" @default.
• W2600586474 hasAuthorship W2600586474A5008183147 @default.
• W2600586474 hasAuthorship W2600586474A5011249298 @default.
• W2600586474 hasAuthorship W2600586474A5015578772 @default.
• W2600586474 hasAuthorship W2600586474A5021969681 @default.
• W2600586474 hasAuthorship W2600586474A5030751316 @default.
• W2600586474 hasAuthorship W2600586474A5032150090 @default.
• W2600586474 hasAuthorship W2600586474A5034324107 @default.
• W2600586474 hasAuthorship W2600586474A5041364373 @default.
• W2600586474 hasAuthorship W2600586474A5051815564 @default.
• W2600586474 hasAuthorship W2600586474A5053977177 @default.
• W2600586474 hasAuthorship W2600586474A5073384798 @default.
• W2600586474 hasAuthorship W2600586474A5075572192 @default.
• W2600586474 hasBestOaLocation W26005864741 @default.
• W2600586474 hasConcept C104317684 @default.
• W2600586474 hasConcept C2776685102 @default.
• W2600586474 hasConcept C2777027569 @default.
• W2600586474 hasConcept C2777058267 @default.
• W2600586474 hasConcept C2777821550 @default.
• W2600586474 hasConcept C2778368673 @default.
• W2600586474 hasConcept C2779259085 @default.
• W2600586474 hasConcept C2779375183 @default.
• W2600586474 hasConcept C4937899 @default.
• W2600586474 hasConcept C501593827 @default.
• W2600586474 hasConcept C547475151 @default.
• W2600586474 hasConcept C55493867 @default.
• W2600586474 hasConcept C71924100 @default.
• W2600586474 hasConcept C86803240 @default.
• W2600586474 hasConcept C89423630 @default.
• W2600586474 hasConcept C94665300 @default.
• W2600586474 hasConceptScore W2600586474C104317684 @default.
• W2600586474 hasConceptScore W2600586474C2776685102 @default.
• W2600586474 hasConceptScore W2600586474C2777027569 @default.
• W2600586474 hasConceptScore W2600586474C2777058267 @default.
• W2600586474 hasConceptScore W2600586474C2777821550 @default.
• W2600586474 hasConceptScore W2600586474C2778368673 @default.
• W2600586474 hasConceptScore W2600586474C2779259085 @default.
• W2600586474 hasConceptScore W2600586474C2779375183 @default.
• W2600586474 hasConceptScore W2600586474C4937899 @default.
• W2600586474 hasConceptScore W2600586474C501593827 @default.
• W2600586474 hasConceptScore W2600586474C547475151 @default.
• W2600586474 hasConceptScore W2600586474C55493867 @default.
• W2600586474 hasConceptScore W2600586474C71924100 @default.
• W2600586474 hasConceptScore W2600586474C86803240 @default.
• W2600586474 hasConceptScore W2600586474C89423630 @default.
• W2600586474 hasConceptScore W2600586474C94665300 @default.
• W2600586474 hasIssue "7" @default.
• W2600586474 hasLocation W26005864741 @default.
• W2600586474 hasLocation W26005864742 @default.
• W2600586474 hasOpenAccess W2600586474 @default.

• next